Innov Clin Neurosci. 2015;12(5–6 Suppl B):3–19. CNS Drug Compounds/Therapies/Devices Long-acting injectable antipsychotics (LAIs) in outpatient treatment of DMS-IV-R schizophrenia Presenters: Bellnier T, Patil K, Ortega T, Seeger G Affiliations: SUNY
Dear Colleagues: Welcome to the March–April 2015 issue of Innovations in Clinical Neuroscience (ICNS). First, I would like to call to your attention the supplement that accompanies this issue of
by Rajshekhar Bipeta, MBBS, DPM, DNB (psych); Srinivasa SRR Yerramilli, MD (psych); Ashok Reddy Karredla, MD (psych); and Srinath Gopinath, MBBS, DPM Dr. Bipeta is a consultant psychiatrist from Rajasri
by Murali K. Kolikonda, MD; Suneela Cherlopalle, MD; Manasa Enja, MD; and Steven Lippmann, MD Drs. Kolikonda, Cherlopalle, Enja, and Lippmann are with the University of Louisville School of Medicine,
by Mitali Wadekar, MD; Anil Sharma, MD, MBA; and Gina Battaglia, PhD Drs. Wadekar and Sharma are with IRB Company, Inc., Buena Park, California, and Dr. Bittaglia is an independent
by Randy A. Sansone, MD, and Lori A. Sansone, MD R. Sansone is a professor in the Departments of Psychiatry and Internal Medicine at Wright State University School of Medicine